Skip to content
Checking whether you are signed in

Moderna, Inc.

MRNANasdaqFull coverage

Price
Loading your watchlists

Latest dossier

AI-generated

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers

How dossiers are written

Q3 of fiscal year 2026 · Published Nov 10, 2026, 8:35 PM UTC

Moderna sells mRNA vaccines against COVID-19, RSV and flu to US wholesalers and pharmacies and to governments abroad, and shares with Merck an individualised cancer therapy, intismeran, that met its Phase 3 goals in melanoma in 2026. Third-quarter 2026 revenue rose 29% to $1.3 billion, all of the growth from multi-year contracts with the UK, Canada and Australia, while US sales were flat and costs fell by about a fifth. The raised 2026 outlook implies a much weaker fourth quarter, and free cash flow over the last twelve months was minus $1.97 billion. Moatsight estimates revenue of about $2.47 billion over the next four quarters and free cash flow of about minus $1.36 billion, so how large intismeran becomes is what decides the company's future.

Read the dossier

What you pay

FigureAt the close5-yr median5-yr range
P/ENo value: no close yetNo value: no price history
EV/SalesNo value: no close yetNo value: no price history
EV/EBITDANo value: no close yetNo value: no price history
Price/FCFNo value: no close yetNo value: no price history
Market capNo value: no close yet
Net debt and other claims(enterprise value minus market cap)No value: no close yet
Enterprise valueNo value: no close yet

How the business is doing

FigureLast 12 months1-year change1-yearYearly, 3 years8 quarters
Revenue$2.5B+13.1%(better for the company)−34.8%Each quarter is listed in the row's details.
Diluted EPS−$6.96n/m, not meaningful: from zero or belown/m, not meaningful: from zero or belowEach quarter is listed in the row's details.
Free cash flow−$2Bn/m, not meaningful: from zero or belown/m, not meaningful: from zero or belowEach quarter is listed in the row's details.
Gross margin28.0%−20.3 pp(worse for the company)−3.2 ppEach quarter is listed in the row's details.
Operating margin−116.0%+39.1 pp(better for the company)−28.9 ppEach quarter is listed in the row's details.
Net margin−110.5%+29.2 pp(better for the company)−24.2 ppEach quarter is listed in the row's details.
Share count430.000MNo value: cannot be derivedNo value: cannot be derivedEach quarter is listed in the row's details.
How to read these figures
  • Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
  • 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
  • Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
  • 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
  • n/m: not meaningful, such as a rate of change from a loss.
  • Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.

Price

No closing prices are stored for this listing yet.

Facts

Exchange
Nasdaq · USD
Kind
Common stock
Security
Common Stock